New study tests herbal vs standard drug for chemo side effect in breast cancer

NCT ID NCT07578064

Recruiting now Disease control Sponsor: Hongxia Wang Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two treatments—Shengbai Oral Liquid (a herbal remedy) and Leucogen tablets (a standard drug)—for moderate neutropenia (low white blood cells) caused by anti-tumor drugs in breast cancer patients. Sixty participants will be randomly assigned to receive one treatment during their first chemotherapy cycle and the other during their second cycle. The goal is to see which treatment better maintains white blood cell counts and reduces the need for additional medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Shengbai Oral Liquid and Leucogen tablets
What this could lead to: If this trial shows Shengbai Oral Liquid works better than Leucogen, it could offer a new option for managing low white blood cell counts in breast cancer patients on chemotherapy.
What could go wrong: This is a small, early-phase study with only 60 participants, so results may not apply to everyone. Both treatments are already approved, so the study is comparing them rather than testing a new cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE MARROW SUPPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm neutropenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE MARROW SUPPRESSION BREAST CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.